B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma
diseaseOn this page
Also known as B-cell lymphoma, unclassifiable, with features Intermediate between diffuse large B-cell lymphoma and Classic Hodgkin lymphomaGray zone lymphomaGrey zone lymphomaHodgkin-like anaplastic large cell lymphomalarge B-cell lymphoma with Hodgkin features
Summary
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma (MONDO:0003658) is a cancer and 15 clinical trials. Top therapeutic interventions include cyclophosphamide anhydrous, prochlorperazine, and bendamustine. A subtype of lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 15
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma |
| Mondo ID | MONDO:0003658 |
| DOID | DOID:5822 |
| NCIT | C37869 |
| UMLS | C1333878 |
| MedGen | 234323 |
| GARD | 0010897 |
| Is cancer (heuristic) | yes |
Also known as: B-cell lymphoma, unclassifiable, with features Intermediate between diffuse large B-cell lymphoma and Classic Hodgkin lymphoma · B-cell lymphoma, unclassifiable, with features Intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma · Gray zone lymphoma · Grey zone lymphoma · Hodgkin-like anaplastic large cell lymphoma · large B-cell lymphoma with Hodgkin features
Disease family
This is a subtype of lymphoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › lymphoma › B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma
Related subtypes (26): prostate lymphoma, nasal cavity lymphoma, bladder lymphoma, tracheal lymphoma, retroperitoneal lymphoma, ureteral lymphoma, ovarian lymphoma, pediatric lymphoma, adult lymphoma, breast lymphoma, heart lymphoma, chest wall lymphoma, lung lymphoma, mediastinal malignant lymphoma, eye lymphoma, B-cell neoplasm, gastrointestinal lymphoma, Hodgkins lymphoma, peripheral T-cell lymphoma, not otherwise specified, composite lymphoma, AIDS-related primary central nervous system lymphoma, primary organ-specific lymphoma, non-Hodgkin lymphoma, extranodal nasal NK/T cell lymphoma, methotrexate-associated lymphoproliferative disorders, progressive transformation of germinal centers
Subtypes (1): mediastinal gray zone lymphoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 15.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 8 |
| PHASE1 | 6 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05507541 | PHASE2 | ACTIVE_NOT_RECRUITING | TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
| NCT05821088 | PHASE2 | RECRUITING | Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma |
| NCT07283822 | PHASE2 | RECRUITING | Amping up With PemJAK |
| NCT00001337 | PHASE2 | COMPLETED | Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin’s Lymphoma |
| NCT01665768 | PHASE2 | COMPLETED | Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma |
| NCT02623920 | PHASE2 | WITHDRAWN | Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma |
| NCT03255018 | PHASE2 | COMPLETED | Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas |
| NCT04860674 | PHASE2 | UNKNOWN | A Prospective Study of PD-1 Inhibitor Combined With ICE in the Treatment of Relapsed/Refractory Gray Area Lymphoma |
| NCT02153580 | PHASE1 | ACTIVE_NOT_RECRUITING | Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia |
| NCT03602157 | PHASE1 | ACTIVE_NOT_RECRUITING | Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL |
| NCT04231877 | PHASE1 | RECRUITING | Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma |
| NCT01943682 | PHASE1 | COMPLETED | Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma |
| NCT02950220 | PHASE1 | COMPLETED | Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma |
| NCT02996773 | PHASE1 | COMPLETED | Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine |
| NCT05208853 | EARLY_PHASE1 | UNKNOWN | An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CYCLOPHOSPHAMIDE ANHYDROUS | 4 | 4 |
| PROCHLORPERAZINE | 4 | 3 |
| BENDAMUSTINE | 4 | 1 |
| DOCUSATE | 4 | 1 |
| GLOFITAMAB | 4 | 1 |
| LACTULOSE | 4 | 1 |
| OMEPRAZOLE | 4 | 1 |
| POLATUZUMAB VEDOTIN | 4 | 1 |
| TAFASITAMAB | 4 | 1 |
| MAPLIRPACEPT | 2 | 1 |
| ONTORPACEPT | 2 | 1 |